 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Press Release
Amplimed, a cancer therapeutics company, has announced that patient enrollment is underway in a pPhase II trial of Amplimexon for injection in combination with gemcitabine in patients with advanced pancreatic cancer.
The multicenter, randomized Phase I1 trial will evaluate Amplimexon (imexon
for injection) plus gemcitabine
versus gemcitabine plus placebo in approximately 124 chemotherapy naive
patients with metastatic pancreatic
cancer.
The purpose of the study is to determine if
Amplimexon in combination with gemcitabine could improve overall
survival as compared to gemcitabine alone. The study will also evaluate and
compare the tolerability and toxicity
of the two treatment arms. The trial is opening at clinical sites throughout
the US.
Evan Hersh, executive vice president and chief medical officer of AmpliMed,
said: "Amplimexon has
demonstrated the ability to overcome resistance and offer an improved safety
profile when combined with
( gemcitabine in preclinical studies of pancreatic cancer, and we look
forward to evaluating the impact of this treatment in randomized clinical
trial
AmpliMed®, Amplimexon® and Amplizone™, are United States trademarks of AmpliMed Corporation.
